Clinical Trials Logo
  1. Home
  2. Mild Alzheimer's Disease
  3. NCT05233774

Lomecel-B Effects on Alzheimer's Disease — CLEARMIND  

Mild Alzheimer's Disease Clinical Trial

Official title:
Lomecel-B Effects on Alzheimer's Disease: A Randomized, Double-Blinded, Placebo-Controlled Phase 2a Trial

Clinical Trial Summary

Dementia resulting from AD is associated with vascular function decline and involves a pro-inflammatory state. In our Phase 1 trial, Lomecel-B treatment met the primary safety endpoint, with no safety concerns, and showed potential to improve clinical assessments. Mechanistically, Lomecel-B treated subjects had higher serum concentrations of pro-vascular and anti-inflammatory biomarkers relative to placebo. This trial builds upon those preliminary Phase 1 results, and is designed to evaluate the safety profile of multiple infusions of Lomecel-B, and to investigate provisional efficacy of single dosing versus multiple dosing of Lomecel-B on cognitive function and biomarkers in AD subjects.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05233774
Study type Interventional
Source Longeveron Inc.
Contact
Status Completed
Phase Phase 2
Start date December 28, 2021
Completion date September 29, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT00243451 - Early Detection of Mild Cognitive Impairment in Individual Patients N/A
Recruiting NCT05872243 - pBFS Guided rTMS Treating Mild Alzheimer's Disease(AD) N/A
Recruiting NCT05417555 - Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease N/A
Terminated NCT01482013 - Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease Phase 1
Completed NCT03186989 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease Phase 1/Phase 2
Not yet recruiting NCT03752294 - A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age. Phase 1
Completed NCT01013610 - An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease Phase 1
Recruiting NCT06058234 - Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
Active, not recruiting NCT03234686 - Deferiprone to Delay Dementia (The 3D Study) Phase 2
Terminated NCT00582855 - Effect of AQW051 in Patients With Memory Impairment Phase 2
Completed NCT01061489 - Sensory-cognitive and Physical Fitness Training in Mild Cognitive Impairment N/A
Completed NCT01548287 - A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment Phase 2
Terminated NCT00706186 - Safety and Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients Phase 4